Tirzepatide Once Weekly for the Treatment of Obesity
2022; Massachusetts Medical Society; Volume: 387; Issue: 3 Linguagem: Inglês
10.1056/nejmoa2206038
ISSN1533-4406
AutoresAnia M. Jastreboff, Louis J. Aronne, Nadia N. Ahmad, Sean Wharton, Lisa Connery, Breno Edson Sendão Alves, Arihiro Kiyosue, Shuyu Zhang, Bing Liu, Mathijs C. Bunck, Adam Stefański,
Tópico(s)Diet and metabolism studies
ResumoObesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known.
Referência(s)